Erythropoietin and cytoprotective cytokines in experimental traumatic brain injury

Methods in Molecular Biology

Volumn 982, Issue , 2013, Pages 141-162

  Gaddam, Samson Kumar ^a   Cruz, Jovany ^a   Robertson, Claudia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anesthesia; Behavior; Brain; Controlled cortical impact; Craniectomy; Erythropoietin; Impactor; Traumatic brain injury

Indexed keywords

CYTOKINE; EPOTRIS; ERYTHROPOIETIN; HELIX B SURFACE PEPTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN BLOOD FLOW; BRAIN CONTUSION; BRAIN PERFUSION; DRUG EFFECT; ERYTHROPOIESIS; HIPPOCAMPUS; HUMAN; INFLAMMATION; INTRACRANIAL PRESSURE; LOCOMOTION; MEMORY; NEUROPROTECTION; NONHUMAN; PARIETAL CORTEX; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN INJURY; DISEASE MODEL; METABOLISM;

ANIMALS; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN;

EID: 84883484068     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-308-4_9     Document Type: Article

References (50)

1. Langlois JA, Rutland-Brown W, Wald MM (2006) The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 21: 375-378
2. McAllister TW et al (2001) Differential working memory load effects after mild traumatic brain injury. Neuroimage 14: 1004-1012
3. Cherian L, Goodman CJ, Robertson CS (2007) Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 322: 789-794
4. Cherian L, Goodman JC, Robertson C (2011) Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats. J Pharmacol Exp Ther 337: 451-456
5. Velly L et al (2010) Erythropoietin 2nd cerebral protection after acute injuries: a doubleedged sword? Pharmacol Ther 128: 445-459
6. Talving P et al (2010) Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 251: 1-4
7. Corwin HL et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288: 2827-2835
8. Corwin HL et al (2007) Efficacy and safety of epoetin alpha in critically ill patients. NEJM 357: 965-976
9. Lin FK et al (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82: 7580-7584
10. Brines M (2010) The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 29: 86-92
11. Sola A et al (2005) Erythropoietin after focal cerebral ischemia activates the Janus kinasesignal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 57: 481-487
12. Kawakami M et al (2000) Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun 279: 293-297
13. Kawakami M et al (2001) Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 276: 39469-39475
14. Solaroglu I et al (2003) Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst 19: 19-22
15. Wu Y et al (2010) Increased expression of erythropoietin receptor in 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine-induced Parkinsonian model. Physiol Res 59: 281-287
16. Wang L et al (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35: 1732-1737
17. Brines ML et al (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97: 10526-10531
18. Meng Y et al (2011) Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. J Neurosurg 115: 550-560
19. Xiong Y et al (2007) Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice. Brain Res 1185: 301-312
20. Yatsiv I et al (2005) Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 19: 1701-1703
21. Zhu L et al (2009) Erythropoietin prevents zinc accumulation and neuronal death after traumatic brain injury in rat hippocampus: in vitro and in vivo studies. Brain Res 1289: 96-105
22. Lu D et al (2005) Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 22: 1011-1017
23. Mahmood A et al (2007) Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 107: 392-397
24. Bohlius J et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532-1542
25. Bohlius JF et al (2005) Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Pract Res Clin Haematol 18: 449-454
26. Xiong Y et al (2010) Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. J Neurosurg 113: 598-608
27. Leist M et al (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239-242
28. Brines M et al (2008) Nonerythropoietic, tissue- protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105: 10925-10930
29. Pankratova S et al (2010) Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 133: 2281-2294
30. Brines M et al (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101: 14907-14912
31. Kanellakis P et al (2010) Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor. Br J Pharmacol 160: 2085-2096
32. Satake R et al (1990) Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. Biochim Biophys Acta 1038: 125-129
33. Erbayraktar S et al (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100: 6741-6746
34. Rodriguez CY et al (2010) Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia. ScientificWorldJournal 10: 2288-2300
35. Gao Y et al (2011) Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro- EPO for ischemic insults to the gerbil brain. J Histochem Cytochem 59: 214-227
36. Adembri C et al (2008) Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit Care Med 36: 975-978
37. Bouzat P et al (2011) Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative. Crit Care Med 39: 2099-2105
38. Xiong Y et al (2011) Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury. J Neurosurg 114: 549-559
39. Ahmet I et al (2011) A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 17: 194-200
40. Ueba H et al (2010) Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U S A 107: 14357-14362
41. Robertson CS et al (2012) Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock. J Neurotrauma 2012;29(6): 1156-1166
42. Cernak I (2005) Animal models of head trauma. NeuroRx 2: 410-422
43. O'Connor WT, Smyth A, Gilchrist MD (2011) Animal models of traumatic brain injury: a critical evaluation. Pharmacol Ther 130: 106-113
44. Cherian L et al (1994) Lateral cortical impact injury in rats: cerebrovascular effects of varying depth of cortical deformation and impact velocity. J Neurotrauma 11: 573-585
45. Cherian L et al (2003) Neuroprotective effects of L-arginine administration after cortical impact injury in rats: dose response and time window. J Pharmacol Exp Ther 304: 617-623
46. Goodman JC et al (1994) Lateral cortical impact injury in rats: pathologic effects of varying cortical compression and impact velocity. J Neurotrauma 11: 587-598
47. Liu H, Goodman JC, Robertson CS (2002) L-arginine reduces neuronal damage after traumatic brain injury in the mouse. J Neurotrauma 19: 327-334
48. Dixon CE et al (1991) A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Methods 39: 253-262
49. Michael LH et al (1995) Myocardial ischemia and reperfusion: a murine model. Am J Physiol 38: H2147-H2154
50. Michael LH et al (1995) Myocardial ischemia and reperfusion: a murine model. Am J Physiol 269:H2147-H2154